When creating a care coordination model, it is important to understand what the model is trying to achieve and what everyone’s roles are in the model, explained Barbara Tofani, RN, MSN, NEA-BC, administrative director of the Hunterdon Regional Cancer Center.
When creating a care coordination model, it is important to understand what the model is trying to achieve and what everyone’s roles are in the model, explained Barbara Tofani, RN, MSN, NEA-BC, administrative director of the Hunterdon Regional Cancer Center.
Transcript
When setting up care coordination teams, what is the education process?
There’s a lot of different models for care coordination. There are models where you have advanced practice professionals—so professionals with Master’s or higher degrees—there are models that you have nurse navigators or nurse coordinators, you have lay coordinators. I don’t know that the formal education preparation matters as much as what is the goal of your care coordination program. And having the right people and the right resources.
If you just say to somebody, “We want you to coordinate cancer care. We want you to be a cancer care coordinator.” And you haven’t identified what the goals are, you can find that people will be floundering, because you can do in a thousand different directions. The model in my organization, initially, was a business model of care coordination. We wanted to make sure that the community cancer center, we felt very strongly that patients are well served getting their care in a community cancer center. So, we wanted to use our care coordinators to help patients get into our system for the care and services that we knew we could provide and provide to the highest level of quality that would be expected of us. And then, for care and services that we did not provide within our organization, help patients get to those tertiary and quaternary facilities to get that care, and then come back to the community.
Because life doesn’t stop just because somebody has cancer. They’re still getting kids off the bus, they’re still working—many of the patients have to work, because their insurance is tied in with their employment. Many, many patients are sandwiched between their parents and their children, so they are caregivers for both ends of the spectrum. None of the stops just because they’ve been diagnosed with a cancer. They have incredibly busy lives and now we’re asking them to shoehorn in chemotherapy and radiation and surgery and then the issues related to fatigue and anxiety and depression and all the other things that go along with a diagnosis of cancer and the treatment of cancer.
So, I think you really have to educate your care coordinators: what is the goal of your program? What is it that we’re looking to achieve? Is it a business model? Is it purely a quality model? Is it an access-to-care model? What is it? And I think everybody has to be clear—I’ll use that same-size-fits-all—you can’t have 1 care coordinator do everything. They have to be very clear as to what is their role, what are the expectations, what are they trying to achieve?
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More